Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OLDIAS2

Financiado

Cerrado

On line Dialysis Sensor Phase2

End-stage renal disease (ESRD) is the most severe form of chronic kidney disease that is an incurable health failure. ESRD is a widespread health issue in developed countries and the patients have only two options: either receive... ver más

31/10/2019

OPTOFLUID TECHNOLO...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

OPTOFLUID TECHNOLOGIES O No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-10-31

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

OPTOFLUID TECHNOLOGIES O

2.82M€ | Lider

Proyectos interesantes

OLDIAS

Medical Technol...

Data Science

71K€ Cerrado

ReTeBESKO

Medical Technol...

Data Science

238K€ Cerrado

RBM-Screen

Medical Technol...

Data Science

71K€ Cerrado

NEPHRON+

Medical Technol...

Data Science

7M€ Cerrado

ablute_

Medical Technol...

Data Science

75K€ Cerrado

Clarity

Medical Technol...

Data Science

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 27 meses Fecha Inicio: 2017-07-21
Fecha Fin: 2019-10-31

Líder del proyecto

OPTOFLUID TECHNOLOGIES O No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto End-stage renal disease (ESRD) is the most severe form of chronic kidney disease that is an incurable health failure. ESRD is a widespread health issue in developed countries and the patients have only two options: either receive permanent renal replacement therapy or undergo surgery to receive a kidney transplant. There are approximately 3.4 million patients worldwide suffering from ESRD that need artificial methods to replace regular kidney functions in their organism. Currently there are no technologies available that would give adequate feedback in real-time on all the important parameters of treatment quality. Optofluid Technologies (OFT) has set out to introduce an online dialysis monitor that utilizes optical techniques. It has developed a prototype that is able to measure all the important uremic biomarker groups in order to provide detailed feedback on the treatment efficiency. A successful SMEI P1 project has been implemented to carry out a detailed feasibility study and OFT is ready to finalize the development in order to bring the novel device to the market. In order to accomplish this OFT is looking to validate the product performance in clinical setting. To ensure the success of the development EU leading hospitals from 5 different member states have been included to carry out the clinical studies. In addition, the leading experts on uremic biomarkers from the EUTox working group will be involved to ensure effective commercialization and communication activities looking to achieve a fast and widespread market acceptance. The planned project will have a wide-spread economic and social impact by influencing all the key stakeholders – scientific and medical community, patients and dialysis equipment manufacturers. As a result of the development project, OFT will generate revenues of up to 73MEUR by 2023.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores